APA引文

Senapati, J., Kantarjian, H., Short, N., Alvarado, Y., Burger, J., Jain, N., . . . Jabbour, E. J. (2022, June). P368: A PHASE II STUDY OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF MEASURABLE RESIDUAL DISEASE-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. HemaSphere.

Chicago Style (17th ed.) Citation

Senapati, J., et al. "P368: A PHASE II STUDY OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF MEASURABLE RESIDUAL DISEASE-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA." HemaSphere Jun. 2022.

MLA引文

Senapati, J., et al. "P368: A PHASE II STUDY OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF MEASURABLE RESIDUAL DISEASE-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA." HemaSphere, Jun. 2022.